This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours

This study has suspended participant recruitment.
(New ultra sound technology have made this present study design less relevant and force us to change the design of the study.)
Information provided by:
Herlev Hospital Identifier:
First received: October 7, 2009
Last updated: October 12, 2010
Last verified: October 2010
Patients with tumors in liver or pancreas are randomized to ultrasound (UL)-guided FNAC biopsies with guidance method or UL-guided FNAC biopsies with free-hand method.

Condition Intervention
Tumors in Liver Tumors in Pancreas Procedure: FNAC (fine needle aspiration cytology)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • quality of obtained biopsy [ Time Frame: one year ]

Secondary Outcome Measures:
  • patients pain and discomfort at procedure [ Time Frame: immediately ]

Estimated Enrollment: 150
Study Start Date: July 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: biopsy arm
patients with tumors in liver and/or pancreas
Procedure: FNAC (fine needle aspiration cytology)
UL guided biopsy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult over 18 years
  • tumors in liver and/or pancreas

Exclusion Criteria:

  • low coagulation factors
  • mentally ill patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00991601

Herlev Hospital
DK-2730, Herlev, Herlev, Denmark, 2730
Sponsors and Collaborators
Herlev Hospital
Principal Investigator: Jakob Burcharth, MD Herlev Hospital
Study Director: Bjørn Skjoldbye, MD Herlev Hospital
  More Information

Responsible Party: Jakob Burcharth, MD., Herlev Hospital, Department of surgical Gastroenterology Identifier: NCT00991601     History of Changes
Other Study ID Numbers: H-KA-05092
Study First Received: October 7, 2009
Last Updated: October 12, 2010

Keywords provided by Herlev Hospital:

Additional relevant MeSH terms:
Gastrointestinal Agents processed this record on June 23, 2017